## **Supplementary Material**

## Biomarker Potential of *LINC00313* in Head and Neck Squamous Cell Carcinoma: Correlation with Epithelial-Mesenchymal Transition and Immune Cell Infiltration

## Yikun Ju<sup>1+</sup>, Fang Zhu<sup>2+</sup>, Bairong Fang<sup>1\*</sup>

+These authors share first authorship.

\*Corresponding Author: Bairong Fang, Department of Plastic and Aesthetic (Burn) Surgery, The Second Xiangya Hospital, Central South University, Changsha, 410011, China. Email: <u>fbrfbr2004@csu.edu.cn</u>




Figure S1. Association between LINC00313 and clinical features. (A) LINC00313 expression in HNSC and normal tissues based on the GEO GSE42743 dataset. (B) Expression of LINC00313 in HNSC patients of different genders. (C) Expression of LINC00313 in HNSC patients of different stages. (D) Expression of LINC00313 in HNSC patients of different T stages. (E) Expression of

LINC00313 in HNSC patients of different N stages. (F) Expression of LINC00313 in HNSC patients of different M stages.




Figure S2. (A) Risk score curve showing survival of patients and expression profiles of LINC00313 in low- and high-risk groups based on ICGC-NHSC dataset. (B) LINC00313 expression correlated with the overall survival rates based on ICGC-NHSC dataset. (C, D, E) The association between LINC00313 and DSS, PFS, DFS of NHSC patients based on TCGA-HNSC dataset.







Figure S3. (A&B) Cell scratch migration experiment. The scale bar is 100µm. \*:P-value < 0.05



**Figure S4. Western Blot raw data. (A)** The same batch of transfected SCC-9 cells, after obtaining the precipitate, were subjected to WB experiments. The experimental results were obtained from two gels and two PVDF membranes, with the same amount of supersampling in each column. (B) Photo and diagram of PVDF membranes before cutting.



**Figure S5. (A)** Correlation between LINC00313 and the TIDE score based on ICGC-HNSC dataset. **(B)** The correlation between LINC00313 and immunotherapeutic response in HNSC patients based on ICGC-HNSC dataset. \*:P-value < 0.05



**Figure S6. (A)** The copy number of LINC00313 was differentially amplified or deleted in the TCGA-HNSC Firehose Legacy dataset and TCGA-HNSC PanCancer Atlas dataset. **(B)** The correlation between the LINC00313 copy number variant and neo-tumorigenesis event after the first treatment in patients with HNSC.




Figure S7. The disease-free rates of patients with altered and unaltered LINC00313 copy number.




Figure S8. Genomics alteration correlation with LINC00313 expression. \*: P-value < 0.05, \*\*: P-value < 0.01.